Wednesday, 19 December 2018

Lupin launches generic solution of pneumonia in US

13 November 2018 | News

Lupin’s Atovaquone Oral Suspension USP, 750 mg/5 mL is the generic equivalent of Glaxosmithkline LLC’s Mepron oral suspension 750 mg/5 mL.

Image credit- lifeextension.com

Image credit- lifeextension.com

Pharma major Lupin has announced the launch of Atovaquone Oral Suspension USP, 750 mg/5 mL having received an approval from the United States Food and Drug Administration (FDA) earlier.

Lupin’s Atovaquone Oral Suspension USP, 750 mg/5 mL is the generic equivalent of Glaxosmithkline LLC’s Mepron® oral suspension 750 mg/5 mL. It is indicated for the prevention of Pneumocystis jirovecii pneuomonia (PCP) in adults and adolescents aged 13 years and older who cannot tolerate trimethoprimsulfamethoxazole (TMP-SMX). It is also for the treatment of mild-to-moderate PCP in adults and adolescents aged 13 years and older who cannot tolerate TMP-SMX.

Atovaquone Oral Suspension USP, 750 mg/5 mL had annual sales of approximately $119 million in the US (IQVIA MAT September 2018).

Comments

× Your session has been expired. Please click here to Sign-in or Sign-up
   New User? Create Account





Survey Box

Does Indian Pharma lack an innovation-friendly ecosystem?

× Please select an option to participate in the poll.
Processing...   View poll results   More polls

× You have successfully cast your vote.
{{ optionDetail.option }}{{ optionDetail.percentage }}%
{{ optionDetail.percentage }}% Complete
More polls